Reset Therapies

I. The Environmental Resets: Accessible Rejuvenation

I. The Environmental Resets: Accessible Rejuvenation Before we explore gene therapies or stem cell transplants, we must acknowledge the "switches" built directly into our biology. As discussed in Chapter 4, our cells possess dormant repair programs (like HSF1 and HIF-1α) that are triggered not by drugs, but by extreme environmental physics: pressure and heat.

1. The Primary Reset: Hyperbaric Oxygen (HBOT) For decades, Hyperbaric Oxygen was used primarily for wound healing. That changed when the Shamir Medical Center in Tel Aviv published a landmark study demonstrating that a specific HBOT protocol could genuinely reverse cellular aging in humans.

• The Results: The study participants showed a >20% increase in telomere length and a 10–37% reduction in senescent cells. This remains one of the only interventions proven to elongate telomeres in human subjects.

• The Mechanism (The Paradox): The magic isn’t just the oxygen; it is the fluctuation. The protocol uses the "Hyperoxic-Hypoxic Paradox." By breathing 100% oxygen at high pressure (2.0 ATA) and then taking a 5-minute air break, the body perceives the rapid drop in oxygen as a "shortage," triggering a massive release of regenerative factors (HIF-1α) without the actual damage of starvation (For a guide on how to schedule strong stressors like HBOT without burning out, see Appendix A).

• The Home Revolution: Historically, 2.0 ATA was the domain of $100,000 clinical hard shells. However, the market has recently been disrupted by direct-to-consumer chambers that can achieve therapeutic pressures. Critical Note: If doing this at home with air (21% oxygen), an Oxygen Concentrator is required to mimic the clinical paradox.

2. The Daily Maintenance: Sauna & Heat Shock Proteins While HBOT acts as a powerful periodic reset, heat therapy serves as the ultimate daily maintenance tool. It does not "turn back time" with the same potency as HBOT or stem cells, but it prevents the accumulation of damage that requires resetting in the first place.

• The Data: Massive longitudinal studies from Finland (tracking 2,000+ men for 20 years) revealed a dose-dependent protection. Men who used the sauna 4–7 times per week had a 40% lower reduction in all-cause mortality and a 66% reduction in dementia compared to those using it once a week.

• The Mechanism (Refolding the Proteins): The secret is Heat Shock Proteins (HSPs). When your core body temperature rises, your cells produce HSPs which act as "molecular chaperones"—physically refolding damaged proteins before they can form the toxic plaques associated with Alzheimer's and vascular disease. Think of Sauna not as a renovation (like HBOT), but as the daily cleaning crew that keeps the building from condemning itself.

II. The Holy Grail: Resetting the Epigenetic Clock

While heat and oxygen can trigger powerful repair mechanisms, the ultimate ambition of geroscience is to reach into the cell's operating system and rewrite the code itself.

The Central Challenge: The central challenge in age reversal is the concept of epigenetic noise. As discussed in Chapter 2, your epigenome—the chemical markers that tell your DNA which genes to turn on or off—accumulates errors over time. If a cell’s decline is encoded in this faulty software, then the ultimate longevity intervention is to reset the software to a factory default, thereby erasing decades of cumulative damage.

Yamanaka Factors: The Code of Youth

​The concept of cellular reset was revolutionized by the discovery of four specific transcription factors—known as the Yamanaka factors (OSKM: Oct4, Sox2, Klf4, and c-Myc). These factors are naturally expressed in early embryos, and when they are introduced into a fully differentiated adult cell (like a skin cell), they trigger a state called induced Pluripotent Stem Cells (iPSCs), effectively wiping the cell's memory clean and reversing its age to zero.

​However, full reprogramming has a major, immediate drawback for a living organism: it erases the cell's identity. If you fully reprogrammed a heart muscle cell, it would forget how to beat and could instead turn into a tumor, known as a teratoma.

​The modern goal is Partial Epigenetic Reprogramming—transiently activating the Yamanaka factors just long enough to rewind the epigenetic clock and promote tissue rejuvenation without losing the cell's specialized function. This is the search for the perfect dial setting between "young" and "tumorous."

From Theory to Mammals: The Ocampo Breakthrough

The transition from petri dishes to living organisms occurred in 2016 with a landmark study by Juan Carlos Izpisua Belmonte’s lab at the Salk Institute (Ocampo et al., 2016). They utilized a "cyclic" protocol on mice engineered to have progeria (rapid aging). Rather than keeping the Yamanaka factors active constantly—which led to death by teratoma within days—they pulsed the factors: two days on, five days off. The results were staggering. The mice did not develop cancer. Instead, their epigenetic clocks slowed, their organ function improved, and their lifespan increased by approximately 30%. This was the first proof of principle that cellular reprogramming could be decoupled from cellular identity in a complex, living mammal.

Refining the Cocktail: The Vision Restoration Model While Ocampo showed life extension, the question remained: Could this restore lost function? In 2020, David Sinclair’s lab at Harvard provided the answer (Lu et al., 2020). They modified the cocktail, removing the oncogene c-Myc and using only three factors (OSK). They delivered this gene therapy via an adeno-associated virus (AAV) into the eyes of mice with glaucoma and age-related vision loss. Remarkably, the treatment did not just halt degradation; it regenerated the optic nerve and restored vision to youthful levels. This study was pivotal because it suggested that mammalian cells retain a "backup copy" of youthful epigenetic information that can be accessed safely without the risk of wiping cellular identity.

The Current Frontier: Chemical Reprogramming The field is now pivoting away from viral gene therapies—which are difficult to turn off once injected—toward safer delivery methods. Companies like Turn Biotechnologies are utilizing mRNA delivered via lipid nanoparticles (similar to COVID-19 vaccines) to pulse the factors transiently. Furthermore, in 2023, researchers identified specific chemical cocktails (small molecules) that can induce reprogramming without introducing external genes at all (Yang et al., 2023). This "Chemical Induced Reprogramming" (CIP) represents a massive leap toward an orally available or topical drug that could rejuvenate tissue without the complexity of gene editing.

III. ​The Promise of Stem Cell Therapy

​The immediate, translatable application of this concept is in advanced Stem Cell and Regenerative Medicine. The aim is to introduce or enhance young, functional cells into an aged system to stimulate repair, which can happen in two primary ways:

1. ​Transplantation of Engineered Cells: Taking pluripotent cells, differentiating them into a specific cell line (e.g., senescent-resistant immune cells), and injecting them to replace or repair damaged tissue.

2. ​In Vivo Reprogramming: Delivering the Yamanaka factors (or other specific longevity genes) directly into the body's tissues via viral vectors (like AAV) to rejuvenate native, aged cells in place. This is significantly safer and easier than cell transplantation.

​The Bleeding Edge: Primates and Systemic Reversal

For years, the field of age reversal faced a translational "valley of death": impressive results in worms and mice failed to materialize in longer-lived mammals. The definitive bridge across this valley was built by Lei et al. (2025). Their study represents a paradigm shift because it moved away from the risky direct injection of Yamanaka factors (which can cause tumors) and instead focused on cell-based delivery of rejuvenation signals.

The Intervention: "Super" Stem Cells The researchers engineered specialized "Senescence-Resistant Cells" (SRCs) by editing the FOXO3 gene—a master regulator of longevity. By modifying two specific phosphorylation sites on this gene, they created mesenchymal progenitor cells that were effectively immune to the toxic environment of an aged body. These were not just young cells; they were "super-competent" young cells designed to survive and repair.

The Results: Quantifying Reversal When these cells were administered intravenously to aged cynomolgus macaques, the results were systemic and statistically profound. The researchers analyzed 61 different tissue types across 10 organ systems using machine-learning-based transcriptomic clocks.

• Biological Age Rollback: The treatment reduced the biological age of the primates by an average of 3.34 years. In the context of the macaque lifespan (roughly one-third of a human’s), this is equivalent to reversing the biological age of a human by approximately 10 to 12 years.

• Systemic Reach: This was not a localized effect. 54% of all analyzed tissues showed significant age reversal. The most dramatic rejuvenation occurred in the hippocampus (restoring cognitive function and memory), the skin (restoring elasticity and barrier function), and the reproductive systems (restoring fertility markers in ovaries and testes).

• Functional Outcomes: Beyond the molecular clocks, the physiological improvements were tangible. The treated animals exhibited a reversal of age-related bone loss (osteoporosis), reduced systemic inflammation, and improved physical mobility.

​This kind of research is critical because it demonstrates that systemic age reversal in a large mammal is possible without triggering uncontrolled growth. It confirms that the molecular information needed for youth is still encoded within our cells, waiting for the right signal to unlock it. The race is now on to develop a safe, precise, and systemic method—be it a molecule, a gene therapy, or a simple injection—that can effectively dial back the epigenetic clock across the entire human body.

​This pioneering work, once translated finally into available treatment, is likely to become the most disruptive force in human health, moving us past pace-slowing therapies and into an era of genuine age restoration.

The "Good Enough" Solution: Wild-Type MSCs 

It is crucial to note that in the Lei et al. study, the "Super Cells" were not the only ones to show results. The researchers compared three groups: those receiving saline (placebo), those receiving genetically engineered cells (SRCs), and those receiving standard, unmodified "wild-type" stem cells. While the engineered cells were superior—roughly 30% more effective at reducing frailty scores—the standard, wild-type cells still delivered approximately 70-75% of the rejuvenation benefit. This is a critical realization for the immediate term: we do not necessarily need to wait for FDA-approved gene-edited therapies to access the majority of these benefits. The "hardware" for age reversal already exists in nature; we just need to source it correctly.

The "Brute Force" Problem: Frequency and Dosage

There is, however, a massive caveat that most clinics will not tell you. The monkeys in the Lei et al. study were not given a single "miracle" infusion. They were treated with a brute force protocol: intravenous infusions every two weeks for 44 weeks. In human terms, that is roughly 22 separate treatments over the course of a year.

• The Monkey Protocol: Constant, high-frequency pulsing of young cells to overwhelm the aged environment.

• The Commercial Reality: Most patients fly to Panama or Mexico once a year for a single "blitz" of cells.

• The Cost Disparity: If you attempted to replicate the monkey protocol at current commercial rates (approx. $20,000 per visit), your annual bill would exceed $440,000. Until the price of cell expansion drops by an order of magnitude, the "brute force" method remains the exclusive domain of billionaires and laboratory animals.

The Global Landscape: A Tiered Guide to Stem Cell Tourism

Currently, no reputable clinic worldwide offers the gene-edited (FOXO3 or Yamanaka factor) cells described in the primate studies. Because the United States classifies expanded allogeneic (donor) stem cells as a "drug" requiring years of clinical trials, even the most effective unedited stem cell treatments are found offshore. Below is a tiered breakdown of the current market, ranging from the "Gold Standard" to the "Wild West."

Tier 1: The Western-Standard Luxury (High Cost / High Safety) 

These clinics operate essentially as American hospitals on foreign soil. They are the go-to for Silicon Valley executives and professional athletes.

• Stem Cell Institute (Panama City, Panama): The "Gold Standard" of the industry. Founded by Neil Riordan, they use proprietary "Golden Cells™"—umbilical cord MSCs selected specifically for their durability and anti-inflammatory potency. The facility is luxurious, corporate, and extremely safety-focused.

  • Cost: ~$25,000+ per visit.

• DVC Stem (Grand Cayman): Located in the tax-neutral Cayman Islands, this clinic leverages the territory’s unique legal status to offer U.S.-quality standards outside of FDA jurisdiction. They are known for high-volume dosing (300 million+ cells) and a "medical resort" vibe.

  • Cost: ~$25,000 per visit.

• BioXcellerator (Medellín, Colombia): Famous for treating UFC fighters, they market aggressively on "potency" and high cell counts. They offer intrathecal (spinal) injections for cognitive enhancement and boast a state-of-the-art lab that rivals any university setting.

  • Cost: ~$18,000 – $25,000.

Tier 2: The Budget High-Volume (Medium Cost / Variable Quality) Mexico has become the "Tijuana Tech" of longevity. The density of clinics drives prices down, but quality control varies wildly.

• The Mexico Corridor (Tijuana / Cancun): Clinics like GIOSTAR, R3, and CPI offer treatments at a fraction of the cost of Panama. The advantage here is accessibility; you can drive across the border. The risk is consistency—some labs are world-class, others are strip-mall operations.

  • Cost: $5,000 – $15,000.

Tier 3: The Legacy & Niche (Specialized / Geopolitical Risk)

• EmCell (Kyiv, Ukraine): Historically the most famous clinic in the world for using fetal stem cells (different from the umbilical cord cells used elsewhere). They have data going back decades. However, due to the ongoing conflict in Ukraine, travel is logistically difficult and dangerous, relegating this once-premier institution to a niche status for only the most determined patients.

  • Cost: ~$10,000 – $15,000 (historically).

(See Appendix F for a current directory of clinics, estimated pricing, and cell types offered).

The Procedures Regardless of the tier, most "systemic anti-aging" protocols share a common methodology:

1. IV Infusion: The primary delivery method. 100 million to 300 million mesenchymal stem cells are delivered intravenously over several days. These cells home in on sites of inflammation.

2. Intrathecal (Spinal) Injection: Offered by aggressive clinics (Tier 1 & 3) to bypass the blood-brain barrier for cognitive enhancement.

3. Exosomes: Often added as a "booster," these are the signaling vesicles shed by stem cells, provided as a concentrated serum to amplify the regenerative signal.

IV. Beyond Cells: The Fringe, The Illegal, and The Experimental

While stem cells represent the hardware of rejuvenation, they are not the only tool in the kit. A sprawling, unregulated ecosystem has emerged to address the other hallmarks of aging—specifically the accumulation of toxic proteins and the degradation of genetic instructions. This is the domain of Regulatory Arbitrage: therapies that are scientifically plausible but legally restricted in the West, driving patients to "Free Cities" like Próspera in Honduras or gray-market clinics in the Caribbean.

1. The "Oil Change": Total Plasma Exchange (TPE) If stem cells are the new parts, this category is the fluid flush.

• The "Vampire" Approach (Young Blood Transfusion): Historically, this garnered the most headlines. Based on parabiosis studies where old mice shared circulation with young mice, companies like Ambrosia offered transfusions of plasma from teenagers to older adults. This approach is ethically controversial to some—raising dystopian concerns about a market in harvesting youth—and has largely fallen out of favor due to inefficiency and immune risks (GvHD).

• The "Dilution" Approach (TPE): The field has largely shifted toward Therapeutic Plasma Exchange. Research by the Conboy Lab at UC Berkeley suggests that aging is driven less by the absence of young factors and more by the accumulation of old, toxic signaling proteins.

  • The Protocol: TPE involves removing a patient's plasma and replacing it with saline and albumin. This effectively "washes" the blood, diluting the pro-aging proteome.

  • Availability: Unlike gene therapy, this is performed legally in the US for autoimmune conditions. Biohackers are now utilizing it "off-label" as a monthly rejuvenation protocol to lower biomarkers of inflammation.

2. The "Poor Man's" TPE: Therapeutic Phlebotomy You do not need $5,000 to start cleaning your blood. A significantly more accessible version of this therapy is simple blood donation.

• The Mechanism: Donating blood (or specifically double-red cell donation) forces the bone marrow to generate fresh, youthful blood cells to replace what was lost.

• The "Dump": Crucially, it physically removes accumulated toxins. Studies suggest that regular donation is one of the most effective ways to lower systemic levels of PFAS ("forever chemicals") and microplastics that accumulate in the plasma.

• Iron Management: It also lowers ferritin (stored iron). High iron levels are pro-aging and pro-oxidative; keeping ferritin in the low-optimal range (similar to pre-menopausal women, who live longer than men partially due to monthly blood loss) is a powerful, free longevity strategy.

3. The Pharmacopeia: Off-Label Longevity Drugs For those unwilling to inject viruses or plasmids, the "gray market" consists of sympathetic doctors prescribing FDA-approved drugs for unapproved longevity purposes. Note that response to these drugs is highly individual.

• Rapamycin (The mTOR Inhibitor): Currently the most robust pharmacological lifespan extender in mouse models. However, human translation is tricky.

  • The "Pause": Notably, both Peter Attia and Bryan Johnson—two of the drug’s biggest proponents—have publicly discussed pausing or stopping their regimens. Johnson discontinued it completely after noting negative side effects (infections, higher resting heart rate) that outweighed the benefits. Attia has expressed growing caution, noting that for some patients, it paradoxically raises lipids and glucose, cancelling out the longevity benefit. If taking this drug, close monitoring of one’s biomarkers and protein levels is advisable.

• SGLT2 Inhibitors (Canagliflozin / Empagliflozin): Originally for diabetes, these are the new darlings of the field. They force the body to excrete glucose in urine, lowering blood sugar and inducing a "fasting-like" state without dietary restriction. In the Interventions Testing Program (ITP), Canagliflozin extended male mouse lifespan by 14%.

• Acarbose: Another ITP winner (for males). It blocks the enzyme that digests starch, effectively turning a high-carb meal into a low-carb one in your gut. It blunts the post-prandial glucose spikes that drive aging.

• 17-alpha Estradiol: A non-feminizing form of estrogen. In male mice, it has shown profound life-extension capabilities without causing the breast tissue growth associated with standard estrogen.

• GLP-1 Agonists (Ozempic / Mounjaro): While famous for weight loss, early data suggests these drugs dramatically lower neuroinflammation, potentially offering protection against Alzheimer’s and Parkinson’s independent of weight.

• Senolytics (Dasatinib + Quercetin):

  • The Protocol: This is a "Hit and Run" therapy. You don't take it daily. You take a high dose for 2–3 days to induce apoptosis (cell death) in senescent "zombie" cells, then stop to let the body clear the debris.

  • The Track Record: In human trials for Idiopathic Pulmonary Fibrosis, this cocktail significantly improved walking distance and reduced inflammatory markers (IL-6) after just a few weeks. It is one of the few interventions with measurable human clinical success in reversing pathology.

• The "Flamed Out": Resveratrol: Once the "red wine" miracle molecule championed by David Sinclair, it has largely fallen out of favor due to poor bioavailability and failure to replicate results in the ITP. Most serious biohackers have switched to NAD+ precursors (NR or NMN), though even those remain debated.

4. The "Software Update": Unregulated Gene Therapy This is the true bleeding edge. In zones like Próspera, Honduras, companies like Minicircle offer reversible gene therapy.

• Follistatin: Users inject a plasmid that instructs cells to overproduce Follistatin, inhibiting myostatin. The result is significant muscle gain and fat loss ("exercise mimetic") lasting 18–24 months.

• Telomerase (hTERT) & Klotho: Pioneered by BioViva (Liz Parrish), these aim to lengthen telomeres and boost cognitive resilience. While data is anecdotal, Parrish claims to have reversed her biological age by decades.

5. The Future: Mitochondrial Transfer (MRT) Lurking on the horizon is the ultimate battery replacement. Aging is fundamentally an energy crisis; as mitochondria degrade, cellular function collapses.

• The Concept: Instead of fixing old mitochondria, why not just pour in new ones?

• The Mechanism: Mitochondria are surprisingly mobile. They can be introduced into the body via "Tunneling Nanotubes" (microscopic bridges between cells) or Endocytosis (cells literally eating the new mitochondria).

• The Players: Companies like Mitrix Bio are developing "mitochondrial transfusions"—bioreactors that grow billions of young, healthy mitochondria which can be injected systemically. They are currently absorbed by immune cells (improving immunity) and eventually by other tissues. This is not yet available in clinics but is rapidly approaching human trials.

6. The Peptide Revolution: "Micro-Dosing" SignalsWhile gene therapy rewrites the code, Peptides are like sending a single, urgent text message to your cells. They are short chains of amino acids that signal specific instructions. This is arguably the most popular "grey market" activity in 2025 because these compounds are legally sold as "Research Chemicals" (not for human consumption) but are widely used for injection.

• BPC-157 (The Healer): Derived from gastric juice, this peptide is legendary in the athletic community for repairing soft tissue. It signals systemic angiogenesis (new blood vessel growth) to heal tendons, ligaments, and the gut lining.

• Epitalon (The Clock Watcher): A synthetic pineal gland peptide originally developed in Russia. It has been shown in rodent and initial human trials to induce telomerase activity, theoretically lengthening telomeres and resetting the circadian rhythm.

• GHK-Cu (The Skin Remodeler): A copper peptide often applied topically or injected. It resets the gene expression of skin cells to a healthier state, tightening loose skin and reducing inflammation.

7. Neuro-Restoration: "Fertilizer" for the Brain Most anti-aging focuses on the body, but the brain ages fastest. The "nootropic" crowd has moved beyond caffeine and Adderall to actual neuro-restorative agents.

• Cerebrolysin: A mixture of neuropeptides derived from pig brains. It acts like a "fertilizer" for neurons, promoting neurogenesis (new brain cell growth). It is standard treatment for stroke in Austria and Russia but is used off-label globally by healthy optimizers to ward off dementia and improve synaptic plasticity.

• Dihexa: A peptide developed at Washington State University that claims to be seven orders of magnitude more potent than BDNF (Brain-Derived Neurotrophic Factor) at helping neurons build new connections.

Epilogue

The Limits of Personal Agency We have spent this entire chapter dissecting the cutting edge of personal optimization. We have cataloged the environmental resets, the stem cell protocols, and the sprawling gray market of off-label pharmacopeia. If you execute everything in this chapter perfectly—if you sleep like Bryan Johnson, train like Peter Attia, and pulse your stressors like a Tel Aviv researcher—you will almost certainly live a longer, healthier life than your peers. But you will still die. And that brings us to the uncomfortable truth that bridges the world of biology to the world of politics.

The Failure of Medicine 2.0

Dr. Peter Attia has famously condemned our current healthcare model—what he calls "Medicine 2.0"—as an abject failure in the context of longevity. Medicine 2.0 is heroic at the end of life; it is miraculous at fixing a gunshot wound, sewing a detached limb back on, or fighting a raging bacterial infection. However, when applied to the "Four Horsemen" of aging (Heart Disease, Cancer, Neurodegeneration, and Metabolic Dysfunction), Medicine 2.0 is not proactive; it is reactive. It waits until the engine has already seized before attempting to change the oil. It treats type 2 diabetes only after insulin resistance has ravaged the vasculature for a decade. It treats Alzheimer’s only after the brain has atrophied. As Attia argues, asking Medicine 2.0 to extend your lifespan is like asking a mechanic to restore a classic car by waiting for it to crash and then fixing the dents. It is a system designed to prolong dying, not to extend living.

The Strategy: The Bridge to LEV

This is where the philosophy of Bryan Johnson merges with the pragmatism of Attia. The ultimate goal is not merely to be a "healthy 90-year-old." The goal is Longevity Escape Velocity (LEV)—the point where science advances fast enough to add more than one year of life expectancy for every year that passes. Once we hit LEV, we are effectively breaking the sound barrier of death. But we are not there yet. The tools in this section—the stem cells, the fasting, the HBOT—are not the warp drive. They are the life raft. Their purpose is to keep your body robust enough, for long enough, to be alive when the real solutions arrive. We are managing our internal biology to buy time for external technology to solve the problem of entropy.

The Systemic Trap

But if the science is accelerating, why does the horizon feel so distant? If we know that TPE dilutes toxic proteins, why can’t you get it at your local clinic? If we know that Rapamycin extends life in every model organism, why is it not standard of care? If we know that early screening saves lives, why does insurance punish you for finding problems too early?

The obstacle is no longer just biological. We have reached the limit of what you can do alone. You can fast, sweat, and inject peptides until you are the fittest corpse in the cemetery, but you cannot live forever inside a system designed to let you die. The ultimate salvation will not come from your kitchen or your gym. It must also come from a medical and regulatory environment that wraps around us, incentivizing rejuvenation rather than profiting from decline. So, what is holding us back? Why, in an age of AI and quantum computing, is our approach to aging still stuck in the 19th century? To answer that, we must look up from the microscope and look at the machine we live in. 

FIGHT THE SYSTEM!